Merck shareholders bless deal for Schering

It's official: Merck got shareholder approval for its $41 billion merger with Schering-Plough, with preliminary vote results showing that more than 99 percent of the stockholders gave a thumbs-up to the deal. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.